Grillot, Nicolas http://orcid.org/0000-0003-2994-1843
Garot, Matthias
Lasocki, Sigismond
Huet, Olivier
Bouzat, Pierre
Le Moal, Charlène
Oudot, Mathieu
Chatel-Josse, Nolwenn
El Amine, Younes
Danguy des Déserts, Marc
Bruneau, Nathalie
Cinotti, Raphael
David, Jean-Stéphane
Langeron, Olivier
Minville, Vincent
Tching-Sin, Martine
Faurel-Paul, Elodie
Lerebourg, Céline
Flattres-Duchaussoy, Delphine
Jobert, Alexandra
Asehnoune, Karim
Feuillet, Fanny
Roquilly, Antoine
Funding for this research was provided by:
Ministère de la Santé et des Services sociaux (PHRCI 2018, API18/N/015)
Article History
Received: 10 January 2021
Accepted: 15 March 2021
First Online: 30 March 2021
Declarations
:
: The REMICRUSH trial protocol has been approved by the ethics committee of The Comité de Protection des Personnes Sud-Ouest et Outre-Mer II and will be carried out according to the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines.Before any study procedures, participants will be informed about the research and freely sign an informed consent form. Patients are eligible to be enrolled without the provision of legal surrogate consent if they cannot express consent due to the emergency situation and if next of kin cannot be informed in the maximal delay for the inclusion. Patients who recover sufficient capacity to provide consent will be asked to consent to continue in the trial. The REMICRUSH study was registered on May 2019 at http://clinicaltrials.gov with trial registration NCT03960801.
: Not applicable—no details, images, or videos relating to an individual person have been collected as part of this publication.
: The authors declare that they have no competing interests.